
Pfizer has suffered a blow to its drug development programme with the withdrawal of pulmonary arterial hypertension (PAH) brand Thelin …
Pfizer has signed an agreement to acquire terguride, a drug for pulmonary arterial hypertension (PAH) currently in phase II testing, …
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

